WCN24-1105 PHARMACOGENETIC RISK FACTORS FOR TENOFOVIR-INDUCED KIDNEY TUBULAR DYSFUNCTION AMONG HIV-POSITIVE ADULTS NIGERIANS

WCN24-1105 PHARMACOGENETIC RISK FACTORS FOR TENOFOVIR-INDUCED KIDNEY TUBULAR DYSFUNCTION AMONG HIV-POSITIVE ADULTS NIGERIANS

Saved in:

Bibliographic Details
Main Authors:	Muzamil Hassan, Raquel Duarte, Victor Mabayoje, Therese Dix-Peek, Caroline Dickens, Akeem Lasisi, Saraladevi Naicker
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924007885
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Corrigendum to “WCN24-1105 PHARMACOGENETIC RISK FACTORS FOR TENOFOVIR-INDUCED KIDNEY TUBULAR DYSFUNCTION AMONG HIV-POSITIVE ADULT NIGERIANS” [Kidney International Reports Volume 9, Issue 4, Supplement, April 2024, Page S339]
by: Muzamil Hassan, et al.
Published: (2024-07-01)

WCN25-3005 Do Transforming Growth Factor-β (TGF-β) Isoforms Predict Chronic Kidney Disease Progression?
by: Alfred Meremo, et al.
Published: (2025-02-01)

Association of chronic inflammation and accelerated atherosclerosis among an indigenous black population with chronic kidney disease.
by: Muzamil Olamide Hassan, et al.
Published: (2020-01-01)

Lower <i>FGFR2</i> mRNA Expression and Higher Levels of <i>FGFR2 IIIc</i> in HER2-Positive Breast Cancer
by: Thérèse Dix-Peek, et al.
Published: (2024-11-01)

An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate
by: Derek E. Murrell, et al.
Published: (2025-05-01)

High Serum Alkaline Phosphatase, Hypercalcaemia, Race, and Mortality in South African Maintenance Haemodialysis Patients
by: Bala Waziri, et al.
Published: (2017-01-01)

WCN24-2537 RISK FACTORS FOR PROGRESSION TO CHRONIC KIDNEY DISEASE AFTER TENOFOVIR-INDUCED ACUTE KIDNEY INJURY
by: Marilia Guimaraes, et al.
Published: (2024-04-01)

Application of <i>Lactobacillus helveticus</i> KLDS 1.1105 Postbiotics for Resisting Pathogenic Bacteria Infection in the Intestine
by: Peng Du, et al.
Published: (2025-07-01)

Pharmacogenetics of carbamazepine
by: N. A. Shnayder, et al.
Published: (2020-01-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

WCN24-2498 RARE KIDNEY COMPLICATIONS WITH IFOSFAMIDE: INSIPIDUS DIABETES AND KIDNEY TUBULAR ACIDOSIS
by: Lorena Fernandes Maia, et al.
Published: (2024-04-01)

WCN24-1421 CLINICAL COURSE OF PRIMARY DISTAL RENAL TUBULAR ACIDOSIS PATIENTS: A RETROSPECTIVE COHORT STUDY
by: Júlia Fernandes do Carmo Las Casas, et al.
Published: (2024-04-01)

Tenofovir Nephrotoxicity: 2011 Update
by: Beatriz Fernandez-Fernandez, et al.
Published: (2011-01-01)

The pharmacogenetics antiepileptic drugs
by: N. A. Shnayder, et al.
Published: (2008-12-01)

Pharmacogenetics of Antiplatelet Drugs
by: Ronan Curtin, et al.
Published: (2002-01-01)

Pharmacogenetics of hypoglycemic agents
by: Irina Vladimirovna Kononenko, et al.
Published: (2015-12-01)

Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020-11-01)

Pharmacokinetics and Pharmacogenetics of Dabigatran
by: A. V. Savinova, et al.
Published: (2021-03-01)

Pharmacogenetics of chemical addictions
by: E. M. Krupitsky, et al.
Published: (2019-12-01)

Pharmacogenetics of antiretroviral drugs
by: Dragović Gordana, et al.
Published: (2012-01-01)

WCN24-1462 RENAL TUBULAR ACIDOSIS AS THE MAIN KIDNEY MANIFESTATION OF SJÖGREN'S SYNDROME: CASE REPORT
by: David Armas, et al.
Published: (2024-04-01)

WCN24-781 COLISTIN-INDUCED ACUTE TUBULAR DYSFUNCTION, ELECTROLYTE IMBALANCES AND ASSOCIATED RENAL OUTCOMES
by: Martin Benjamin Yama Estrella, et al.
Published: (2024-04-01)

Evaluation of the efficacy of a South African psychosocial model for the rehabilitation of torture survivors
by: Dominique Dix-Peek, et al.
Published: (2018-05-01)

CONDIÇÃO DO CONHECIMENTO EM ETHICA NICOMACHEA II.4,1105A 31: UMA NOVA LEITURA SOBRE O PARTICÍPIO “EIDŌS”
by: Ahmad Suhail Farhat
Published: (2025-02-01)

Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
by: Shenglong Lin, et al.
Published: (2024-11-01)

WCN24-548 DISTAL RENAL TUBULAR ACIDOSIS PRESENTING WITH HYPOKALEMIC PARALYSIS AS INITIAL MANIFESTATION OF SJOGREN'S SYNDROME
by: Barbara Jones, et al.
Published: (2024-04-01)

Pharmacogenetics of Community-Acquired Pneumonia
by: S. SH. Suleimanov, et al.
Published: (2020-05-01)

Editorial: Pharmacogenetics of psychiatric disorders
by: Sarah Allegra, et al.
Published: (2025-01-01)

WCN24-1064 An International Tale of Hypothyroidism
by: Nithiakishna Selvathesan, et al.
Published: (2024-04-01)

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
by: Ping‐Feng Wu, et al.
Published: (2024-12-01)

WCN24-1244 BUTYRATE IMPROVES THE METABOLISM OF PROXIMAL TUBULAR CELLS AND ATTENUATES RENAL INJURY IN OXALATE-INDUCED AKI
by: Orestes Foresto-Neto, et al.
Published: (2024-04-01)

Droplet Digital PCR: A New Molecular Method to Detect G1105S/V Mutations in <i>Plasmopara viticola CesA3</i> Gene
by: Helene Sánchez-Zelaia, et al.
Published: (2024-11-01)

WCN25-909 CLINICAL AND GENETIC CHARACTERISTICS OF DISTAL RENAL TUBULAR ACIDOSIS IN CHILDREN
by: Larisa Prikhodina
Published: (2025-02-01)

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV
by: Nicole Marie Lioufas, et al.
Published: (2018-06-01)

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate
by: Hamed Mirmoezzi, et al.
Published: (2025-03-01)

Clinical Relevance of Pharmacogenetics in Serotonin Syndrome
by: Dehuti Pandya, et al.
Published: (2020-01-01)

Pharmacogenetics and Age-Related Macular Degeneration
by: Stephen G. Schwartz, et al.
Published: (2011-01-01)

PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS
by: A. L. Khokhlov, et al.
Published: (2018-02-01)

Editorial: Insights in pharmacogenetics and pharmacogenomics: 2023
by: José A. G. Agúndez, et al.
Published: (2025-01-01)

Pharmacogenetic aspects of substance use disorders
by: A. O. Kibitov
Published: (2018-07-01)